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OBJECTIVES Using a transgenic mouse model of myocardial-targeted overexpression of the wild-type a1B
adrenergic receptor (AR) (Tga43), we studied the role of the bAR kinase (bARK1) in the
evolution of myocardial hypertrophy and its transition to heart failure (HF).
BACKGROUND Increased myocardial expression of bARK1 has been shown to be associated with HF and
certain models of hypertrophy.
METHODS Tga43 mice and their nontransgenic littermate controls were treated with the a1AR agonist
phenylephrine (PE) for 3, 7 or 14 days to characterize the cardiac consequences.
RESULTS Nontransgenic littermate control mice treated for 14 days with PE display cardiac hypertro-
phy with no increase in bARK1 expression. However, Tga43 animals show a reduced
tolerance to 14-day PE treatment, demonstrated by reduced survival and severe cardiac
hypertrophy. Moreover, PE treatment for three and seven days in Tga43 mice resulted in an
exaggerated hypertrophic response accompanied by significant cardiac biochemical abnor-
malities that are normally associated with HF, including fetal gene expression, reduced bAR
density and enhanced bARK1 expression. We also found reduced myocardial stores of the
sympathetic neurotransmitter neuropeptide Y.
CONCLUSIONS These data suggest that PE-treated Tga43 mice have chronic activation of the cardiac
sympathetic nervous system, which may be responsible for the appearance of apparent
maladaptive hypertrophy with an evolution towards HF and sudden death. Thus, the cardiac
phenotypes found in these mice are not the direct result of enhanced a1BAR signaling
and suggest that bARK1 is a key molecule in the transition of myocardial hypertrophy to HF.
(J Am Coll Cardiol 2001;38:534–40) © 2001 by the American College of Cardiology
Myocardial hypertrophy is believed to be a mechanism of
compensation that the heart activates to stabilize its perfor-
mance in the presence of an injury or increased wall stress
(1). Physiologic myocardial hypertrophy is often observed in
athletes and can be considered an adaptive mechanism to
support cardiac performance in the presence of an increased
workload (2). However, when hypertrophy is induced be-
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cause of a cardiac insult (i.e., cardiac overload), it often
becomes maladaptive as it increases the metabolic needs of
the myocardium and worsens cardiac performance.
Molecular mechanisms involved in the transition from
hypertrophy to heart failure (HF) are not well understood.
Several studies have demonstrated a role of signaling
through heterotrimeric guanine nucleotide binding (G)
proteins and their associated G protein-coupled receptors
(GPCRs). Signaling through two G proteins, Gq and Gs,
appears to be critically involved in both hypertrophy and
failure. Signaling through Gq-coupled receptors such as the
a1AR, the angiotensin II receptor and the endothelin I
receptor has been shown to be quite effective at stimulating
hypertrophy of the cardiac myocyte (3–5). Moreover, trans-
genic mice with myocardial-targeted overexpression of a
constitutively activated mutant (CAM) of the a1BAR dis-
play modest cardiac hypertrophy (6). We have previously
shown that Gq plays an obligatory role in the triggering of
in vivo pressure overload ventricular hypertrophy (7). In
addition, transgenic mice have also shown that overexpres-
sion of Gaq itself, either a wild type or a CAM form, results
in significant myocardial hypertrophy, which leads to a state
of decompensation and HF (8,9).
In the failing heart, a constellation of abnormalities are
present within the myocardial bAR-Gs-cyclic adenosine
monophosphate (cAMP) system. These include the down-
regulation of receptor density (10) and enhanced expression
and activity of the bAR kinase-1 (bARK1) (or GRK2) (11),
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which is a G protein-coupled receptor kinase (GRK) that
can phosphorylate and desensitize several GPCRs, includ-
ing bARs (12). Interestingly, bARK1 may be one of the
common links between hypertrophy and failure, as several
studies in genetically engineered mice have found bARK1
to be a critical regulator of cardiac function under normal
conditions and also during myocardial hypertrophy and HF
(12–17).
Importantly, one study linking bARK1 to both Gq and
Gs signaling in the heart has been carried out in transgenic
mice with cardiac-specific overexpression of the wild-type
a1BAR (Tga43) (18). In this study, enhanced in vivo
signaling through the a1AR-Gq pathway, which is present
in Tga43 mice, leads to significant desensitization of the
myocardial bAR system, which was found to be at least
partially due to enhanced activity of bARK1 (18). Interest-
ingly, bARK1 is not elevated in myocardial hypertrophy
induced by chronic a1AR-agonist phenylephrine (PE) or in
the CAM a1BAR transgenic mice (17). Moreover, it is not
elevated in hypertrophic Gaq transgenic mice (19). Thus,
the Tga43 mice represent a unique and powerful model to
study the role of bARK1 in myocardial Gq and Gs coupled
signal transduction. In the present study, we sought to
investigate the consequences of PE treatment in Tga43
animals and to further investigate the role of bARK1 in the
cardiac biochemistry of these mice.
METHODS
Animals, study design and pump implantation. Tga43
mice were generated in our laboratory and have already been
described (6,18). These mice have a cardiac a1AR density of
;1.5 pmol/mg of membrane protein, which corresponds to
70-fold over nontransgenic littermate control (NLC) mice
cardiac membrane a1AR density (;20 fmol/mg of mem-
brane protein). Tga43 and NLC mice three to six months
old weighing 25 to 30 g were utilized in this study. The
institutional animal usage committee at Duke University
approved all animal procedures. Mini-osmotic pumps (Al-
zet model 2002, Palo Alto, California) were implanted as
previously described (16,17). Pumps were set to deliver PE
at 100 mg/kg/day or vehicle (phosphate-buffered saline) as
a sham treatment. At 3, 7 and 14 days of treatment,
individual heart weight-to-body weight ratios were calcu-
lated (mg/g) following removal of hearts from anesthetized
animals. On day 7, a group of mice was anesthetized with a
mixture of ketamine (10 mg/kg) and xylazine (0.5 mg/kg),
and a polyethylene catheter (PE-10) was inserted into the
right common carotid artery to measure systolic blood
pressure as described (18).
Histology. After 14 days, three animals from each group
were anesthetized and the hearts were perfusion fixed, as
described (17). Histological staining of myocytes was done
with Masson’s trichrome by standard protocols (15).
Ligand binding assays and measurement of adenylyl
cyclase activity. Membrane fractions were prepared from
hearts and a1AR or bAR binding was carried out as
described (16–18). bAR responsiveness was assessed as the
percent increase in cAMP production induced by the bAR
agonist isoproterenol compared with production under
baseline conditions using methodology previously described
(12,15).
bARK1 immunoblotting and GRK activity assays. Im-
munodetection of myocardial levels of bARK1 was per-
formed on detergent-solubilized extracts following immu-
noprecipitation, as we have previously described (16,17). G
protein-coupled receptor kinase activity was assessed on
cytosolic myocardial extracts using rhodopsin as a substrate
as described (16,17).
Neuropeptide Y assays. Neuropeptide Y was assessed on
the clarified samples using a commercially available radio-
immunoassay according to the manufacturer’s instructions
(Peninsula Laboratories Inc., San Carlos, California).
Ribonucleic acid (RNA) extraction and Northern blot.
Ventricular tissue was separated from the atria under a
dissecting microscope. Total ribonucleic acid was isolated
using RNAzol (Biotecx, Houston, Texas), a one-step
guanididium-based extraction solution. Northern blots were
carried out as described (18).
Statistical analysis. Effects of treatment on animal survival
were estimated by a chi-square test. For multiple compari-
sons, two-way analysis of variance was used with one
between (strain) and one within (treatment) factor. A
one-way analysis of variance was also applied for compari-
sons between two groups. The null hypothesis was discarded
when p , 0.05. Data are presented as mean 6 SE.
RESULTS
Heart weight-to-body weight ratios and histological
measurements. Chronic PE treatment was poorly toler-
ated by Tga43 mice. Survival was reduced in the transgenic
mice to ;40% after 14 days of treatment, which was
statistically lower compared with PE treatment in NLC
mice (Fig. 1A). Blood pressure measurements confirmed
that Tga43 mice have lower systolic blood pressure com-
Abbreviations and Acronyms
ANF 5 atrial natriuretic factor
AR 5 adrenergic receptor
bARK1 5 bAR kinase-1
CAM 5 constitutively activated mutant
cAMP 5 cyclic adenosine monophosphate
du 5 densitometry units
GPCR 5 G protein-coupled receptor
GRK 5 G protein-coupled receptor kinase
HF 5 heart failure
mRNA 5 messenger ribonucleic acid
NLC 5 nontransgenic littermate control
PE 5 phenylephrine
SERCA2a 5 sarcoplasmic reticulum Ca11-ATPase
Tga43 5 transgenic mice with cardiac targeted
overexpression of the wild-type a1B-AR
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pared with NLC mice (NLC, n 5 10: 120 6 5 mm Hg;
TGa43, n 5 10: 104 6 5 mm Hg; p , 0.05 vs. NLC) as
previously described (18). Phenylephrine treatment in-
creased systolic blood pressure in both NLC and Tga43
mice, which was still higher in NLC compared with Tga43
mice (NLC, n 5 7: 168 6 3 mm Hg; Tga43, n 5 10:
140 6 3 mm Hg; p , 0.05 vs. NLC).
Heart-to-body weight ratio was assessed at 3, 7 and 14
days as a measure of the hypertrophic response of the heart
to PE treatment. A hypertrophic response to PE treatment
was observed in NLC mice after 7 days with no further
increase in heart size at 14 days of PE treatment (Fig. 1B).
However, in the Tga43 mice treated with PE, a significant
hypertrophic response was already present at 3 days, which
was similar to that observed in NLC mice treated with PE
for 7 or 14 days (Fig. 1B). In a subset of animals, we
measured the heart-to-tibia-length ratio and after seven
days of PE treatment, the heart-to-tibia-length ratio was
significantly higher in Tga43 mice compared with NLC
mice (Tga43: 9.3 6 0.4, n 5 9; NLC: 8.4 6 0.1; n 5 9;
p , 0.05).
Histologically, sham-treated Tga43 mice had a normal
macroscopic heart appearance, which was indistinguishable
from NLC hearts. However, PE-treated Tga43 hearts
showed pericardial and pleural effusions as well as cardio-
megaly with global chamber dilation that was not seen in
PE-treated NLC mice or sham-treated Tga43 animals
(Fig. 2A). In .60% of hearts, the presence of organized
thrombi in atria was observed (Fig. 2B). Upon microscopic
examination, other differences in these models were found
(Fig. 2C–F). Phenylephrine treatment of NLC mice did not
cause significant necrosis, fibrosis or myofiber disarray
compared with sham-treated NLC mice (Fig. 2C and D).
Similarly, sham-treated Tga43 hearts presented with a
normal microscopic appearance (Fig. 2E). However, 14 days
of PE treatment in Tga43 mice caused increased collagen
deposition (Fig. 2F). Because of the severity of the PE-
response at 14 days and the lack of surviving animals in
Tga43 mice, all further biochemical and functional assess-
ments were performed after 7 days of treatment with PE. In
Tga43 mice, seven days of PE treatment still led to
exaggerated hypertrophic responses compared with PE-
treated NLC mice (Fig. 1B).
Cardiac a1AR density. As expected, PE induced a signif-
icant reduction in cardiac a1AR density in NLC mice
because of agonist-mediated downregulation (sham: 23.9 6
1.3 fmol/mg membrane protein, n 5 5; PE: 14.5 6
2.4 fmol/mg membrane protein, n 5 5, p , 0.01). Inter-
estingly, PE also induced a reduction in the transgenic
a1AR density in Tga43 mice (sham: 1,560 6 76 fmol/mg
membrane protein, n 5 6, PE: 1,172 6 139 fmol/mg
membrane protein, n 5 6, p , 0.05).
Cardiac bAR density and signaling. We also examined
the myocardial bAR signaling system in the hearts of NLC
and Tga43 mice treated with PE. Treatment for seven days
with PE did not alter bAR density in NLC mice (sham:
34.5 6 2.4 fmol/mg membrane protein, n 5 8; PE: 37.6 6
3.4 fmol/mg membrane protein, n 5 9, p 5 ns). bAR
density in sham-treated Tga43 mice was similar to NLC
mice (34.6 6 2.9 fmol/mg membrane protein, n 5 9),
however, PE-treated Tga43 animals displayed a significant
reduction in myocardial bAR density (25.2 6 2.9 fmol/mg
membrane protein, n 5 9, p , 0.05 vs. sham-treated
Tga43). bAR signaling was assessed by measuring mem-
brane adenylyl cyclase activity. Phenylephrine treatment of
NLC and Tga43 mice did not alter membrane adenylyl
cyclase activation either basally (NLC: sham: 39 6 3
pmol/mg/min [n 5 6]; PE: 34 6 10 [n 5 6], p 5 ns;
Tga43; sham: 39 6 3 pmol/mg/min [n 5 12], PE: 40 6 4
[n 5 11], p 5 ns) or in response to 10 mM NaF (NLC;
sham: 323 6 25 pmol cAMP/mg/min [n 5 6]; PE: 360 6
18 [n 5 6], p 5 ns; Tga43; sham: 290 6 28 pmol/mg/min
[n 5 12], PE: 267 6 22 [n 5 11], p 5 ns), indicating that
the content and activity of G proteins and that of adenylyl
cyclase were not affected by the treatment. Phenylephrine
did not affect bAR responsiveness in NLC mice; however,
in Tga43 animals the bAR-mediated response to isopro-
terenol was impaired as compared with NLC mice as we
Figure 1. Effects of phenylephrine (PE) treatment (100 mg/kg/day) on
survival and cardiac mass in nontransgenic littermate control (NLC) mice
and transgenic mice with cardiac targeted overexpression of the wild-type
a1B-AR (Tga43). (A) Survival (%) in NLC (n 5 15) and Tga43 (n 5 27)
animals after chronic PE administration. Perioperative mortality was about
10% and was not different between NLC and Tga43 mice. *p , 0.05,
Tga43 versus NLC (x2 test). (B) Heart-to-body weight ratio (mg/g)
assessed after 3, 7 and 14 days of PE treatment in Tga43 and NLC mice.
In order to simplify the graph, the data of the sham animals represent the
average of each time point, as no difference was observed between them.
*p , 0.05 versus sham phosphate-buffered saline treated mice; #p , 0.05
versus PE-treated NLC mice.
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have previously described (18), and PE treatment further
worsened this response (Fig. 3A).
bARK1 expression and activity. One explanation for
decreased bAR responsiveness is enhanced activity of
bARK1. In NLC hearts, bARK1 expression assessed by
Western blot technique was not altered by PE treatment
(sham: 31,061 6 1,028 densitometry units [du], n 5 7; PE:
32,267 6 2,110 du, n 5 6; p 5 not significant) confirming
our previous observations in PE-treated wild-type mice
(17). In sham-treated Tga43 animals, myocardial bARK1
levels were similar to NLCs (26,024 6 6,296 du, n 5 11,
p 5 not significant vs. NLC sham). Interestingly, unlike
what was observed in PE-treated NLC mice, PE induced a
twofold increase in the expression of this GRK in the hearts
of Tga43 mice (Fig. 3B). This increased expression of
bARK1 resulted in a significant increase in myocardial
GRK activity assessed in PE-treated Tga43 hearts com-
pared with sham-treated Tga43 hearts (data not shown).
Cardiac neuropeptide Y levels. Neuropeptide Y is co-
released with norepinephrine from sympathetic nerve ter-
minals and chronic firing of the sympathetic nervous system
results in a faster tissue depletion of this neurotransmitter.
Figure 2. Morphological and histological assessment of the cardiac effects of phenylephrine (PE) treatment in transgenic mice with cardiac targeted
overexpression of the wild-type a1B-AR (Tga43) and nontransgenic littermate control (NLC) mice. (A) Morphology of two Tga43 littermates that were
either phosphate-buffered saline (left) or PE (right) treated for 14 days. The heart of the sham phosphate-buffered saline treated Tga43 mouse is
indistinguishable from a phosphate-buffered saline-treated NLC mouse (not shown). However, as shown on the right, PE treatment increases the size of
cardiac chambers, including left and right atria in Tga43 mice. (B) Magnified section of a PE-treated Tga43 heart showing an enlarged left atria with the
presence of thrombi, which was seen in .60% of the PE-treated Tga43 mice. (C) Masson trichrome stained section of a representative phosphate-buffered
saline treated (sham) NLC mouse taken from the left ventricular wall toward the apex. (D) A similar section taken from a PE-treated (14 days) NLC mouse.
(E) A stained section from a sham-treated Tga43 mouse showing no fibrosis. (F) Representative left ventricular section from a PE-treated (14 days) Tga43
mouse showing significant deposition of collagen and fibrosis (staining blue), which was seen in all Tga43 animals after PE.
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Thus, a reduction in the cardiac content of neuropeptide Y
is suggestive of chronic activation of the sympathetic ner-
vous system in the heart (20). Cardiac levels of neuropeptide
Y were similar between sham-treated and PE-treated NLC
mice as well as sham Tga43 mice; however, in PE-treated
Tga43 animals, the cardiac content of neuropeptide Y was
significantly reduced by ;20% (Fig. 4).
Cardiac expression of fetal genes. To determine whether
PE treatment altered the pattern of hypertrophy/HF gene
expression in the hearts of NLC versus Tga43 mice, we
assessed the expression of fetal genes that are modified in
human and animal models of hypertrophy and HF such as
atrial natriuretic factor (ANF) and skeletal a-actin (21,22).
We also examined the mRNA expression of the sarcoplas-
mic reticulum Ca11-ATPase (SERCA2a), which is re-
duced in experimental and human HF (23,24). Phenyleph-
rine treatment in NLC mice did not affect the ventricular
expression of ANF, skeletal a-actin or SERCA2a (Fig. 5).
We confirmed our previous findings that compared with
NLC mice, Tga43 animals have increased levels of ventric-
ular ANF expression (6,18), and made the novel observation
that the expression of the skeletal a-actin gene is also
enhanced in Tga43 mouse hearts compared with NLC
hearts (Fig. 5). In addition, no significant difference was
observed in the levels of SERCA2a mRNA between sham-
treated Tga43 and NLC hearts (Fig. 5). Interestingly, in
Tga43 mice, no further increase in ANF and a skeletal
actin was detected after chronic PE treatment; however,
there was a significant reduction in the expression of
SERCA2a (Fig. 5).
DISCUSSION
The present study focuses on the transition of myocardial
hypertrophy towards HF in transgenic mice with cardiac
overexpression of the wild-type a1BAR (Tga43) chronically
treated with PE. Important to this model is that normally
the overexpression of the a1BAR in the heart of Tga43 mice
is not associated with negative effects on growth or mortality
(18,25). The administration of PE to NLC mice results in
moderate cardiac hypertrophy, whereas in Tga43 mice,
chronic infusion of PE results in increased mortality asso-
ciated with exaggerated cardiac hypertrophy, fibrosis and
biochemical characteristics of HF.
Exaggerated hypertrophy and HF in Tga43 mice. Inter-
estingly, Tga43 mice have normal cardiac size. However,
PE treatment caused exaggerated and severe hypertrophy,
which is in contrast to the relatively benign effects of chronic
PE administration in NLC mice. We found several changes
in cardiac gene expression consistent with a decompensated
state of myocardial function. These included a decrease in
ventricular SERC2a mRNA levels and increased ventricular
expression of ANF and skeletal a-actin, which have previ-
ously been observed in several models of maladaptive
hypertrophy and HF (21–24). Interestingly, untreated or
sham-treated Tga43 mice already have significantly ele-
vated ventricular mRNA levels of ANF and skeletal a-actin,
which is surprising because these mice do not normally
present with cardiac hypertrophy (6,18). Moreover, bAR
density was decreased as well as adenylyl cyclase activity,
which are characteristics of the failing heart. Importantly,
Figure 3. Effect of seven days of PE infusion on (A) myocardial
b-adrenergic receptor (AR) responsiveness and (B) bAR kinase 1
(bARK1) levels in nontransgenic littermate control (NLC) hearts and the
hearts of transgenic mice with cardiac targeted overexpression of the
wild-type a1B-AR (Tga43). (A) The activity of adenylyl cyclase from
cardiac membranes was assessed basally and after isoproterenol (ISO)
stimulation (1024M). Data are expressed as the mean 6 SEM of
ISO-stimulated activity over the activity seen under basal conditions (n 5
6 to 12). *p , 0.05 versus sham (phosphate-buffered saline) treatment;
#p , 0.05 versus PE-treated NLC mice. (B) Myocardial levels of bARK1
as measured by semiquantitative Western blotting following immunopre-
cipitation of cardiac extracts with a monoclonal bARK1/2 antibody (16).
Shown is the mean 6 SEM of sham-treated NLC (n 5 7) and Tga43
(n 5 11) mice compared with PE-treated (7 days) NLC (n 5 6) and
Tga43 (n 5 10) mice. bARK1 levels in all mice were normalized to the
levels found in sham (phosphate-buffered saline) NLC mice. Shown in the
inset is a representative immunoblot of bARK1 levels. *p , 0.05 versus
sham-treated mice; #p , 0.05 versus NLC mice.
Figure 4. Effects of phenylephrine (PE) treatment (7 days) on myocardial
neuropeptide Y content in nontransgenic littermate control (NLC) mice
and transgenic mice with cardiac targeted overexpression of the wild-type
a1B-AR (Tga43). Shown is the mean 6 SEM of 6 to 10 mice in each
group. *p , 0.05 versus sham-treated mice; #p , 0.05 versus NLC mice.
White bar 5 NLC; black bar 5 Tga43.
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PE treatment of NLC mice does not lead to these changes.
Interestingly, Tga43 mice have normal bAR density, but
previously we did show that bAR-mediated adenylyl cyclase
activity was decreased because of heightened activity of
bARK1 (confirmed in this study) and Gai (18,25). This
uncoupling was progressive in the present study because of
the increased expression of bARK1 as well as activity.
Overall, these signaling results suggest that as a conse-
quence of a1AR overexpression, Tga43 hearts are “primed”
for a hypertrophic response and chronic PE treatment
exaggerates this response. However, this response not only
leads to severe hypertrophy as a result of enhanced
a1AR-Gq signaling but continues through apparent de-
compensation characterized by severe cardiac fibrosis, mo-
lecular changes consistent with HF and sudden death.
Enhanced sympathetic overdrive and bARK1 expression.
Further supporting the conclusion that PE causes Tga43
mice to enter a state of decompensation and HF is the
finding that cardiac stores of neuropeptide Y were reduced,
indicating chronic activation of the sympathetic nervous
system (20). This is a finding that was not evident in
PE-treated NLC mice. Thus, it appears that deterioration
of the state of Tga43 hearts after chronic PE exposure
results in increased catecholamine outflow as a mechanism
of adaptation and cardiac stimulation. This means that not
only is a1AR-Gq signaling enhanced, but so is signaling
through the bAR-Gs pathway. Activation of the cardiac
sympathetic nervous system plays an important role in the
development of HF. One role of enhanced sympathetic
nervous system activity that may be critically important in
our current model is the induction of bAR downregulation
and uncoupling of bAR signaling because of bARK1
upregulation, which was present in the PE-treated Tga43
hearts. This does not occur in either PE treatment of NLC
mice or in untreated Tga43 mice. Consistent with this
hypothesis is the fact that we have previously shown that
bARK1 expression in the heart is increased after chronic
catecholamine exposure (16,17).
The role of bARK1 in the transition to HF. Evidence is
mounting that bARK1 plays a critical role in the pathogen-
esis of HF (15,26–28). Increased bARK1 expression pre-
cedes the development of frank cardiomyopathy in several
experimental models of HF (26,28,29). Moreover, inhibit-
ing the activity of myocardial bARK1 appears to be a novel
therapeutic target for improving the function of the failing
heart. Transgenic mice overexpressing a peptide inhibitor of
bARK1 (bARKct) have increased basal and catecholamine
induced contractility (12). When these bARKct expressing
mice were crossbred with a genetic mouse model of HF
induced by the knockout of the MLP gene, the resultant
hybrid animals had normal cardiac size and function,
demonstrating a HF “rescue” after bARK1 inhibition (15).
More recently, a study has been carried out in rabbits
demonstrating the importance of bARK1 in the pathogen-
esis of HF development following myocardial infarction
where rabbits treated with a bARKct adenovirus at the time
of myocardial infarction had significantly delayed HF pro-
gression (26).
Concerning the present study, it is important to note that
enhanced expression of bARK1 is not a generalized phe-
nomenon accompanying myocardial hypertrophy, because
bARK1 is not elevated in several other models of hypertro-
phy (13,17). These include transgenic models of cardiac
hypertrophy attributable to p21ras overexpression (13) or
CAM-a1BAR overexpression (17). Moreover, as confirmed
by the present study, NLC mice treated with PE had
normal myocardial bARK1 expression despite the presence
of myocardial hypertrophy. Therefore, our present results
add to the data supporting the hypothesis that myocardial
bARK1 expression is controlled by bAR signaling. In this
regard, we have demonstrated that, in the heart, changing
the functional state of bARs can specifically modulate
bARK1 expression (16). Chronic infusion of the bAR
agonist isoproterenol was associated with an increase in
cardiac bARK1 content whereas, reciprocally, inactivation
Figure 5. Effects of phenylephrine (PE) treatment (14 days) on myocardial
gene expression in nontransgenic littermate control (NLC) mice and
transgenic mice with cardiac targeted overexpression of the wild-type
a1B-AR (Tga43). (A) Representative Northern blot analysis of the
ventricular transcript level of atrial natriuretic factor (ANF), skeletal
a-actin, sarcoplasmic reticulum Ca11-ATPase (SERCA2a) and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) in the listed mice
phosphate-buffered saline and PE treated. (B) Pooled quantitative data for
the individual genes shown in A. Histograms represent the mean 6 SEM
of quantified Northern blots using the ribonucleic acid isolated from three
left ventricles in each group. The data were normalized to the levels of
hybridization of GAPDH and plotted as foldover GAPDH levels. *p ,
0.05 versus sham-treated NLC mice.
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of the bARs by chronic administration of the bAR antag-
onists atenolol and carvedilol resulted in reduction of
bARK1 and a subsequent increase in myocardial bAR
signaling (16). Of note, chronic stimulation of cardiac
a1ARs does not alter bARK1 expression in the hearts of
wild-type mice (17). Thus, enhanced sympathetic nervous
activity resulting from cardiac injury such as the severe
(maladaptive) hypertrophy induced by PE treatment of
Tga43 mice can enhance bARK1 expression via bAR
signaling. In conclusion, our current results showing in-
creased bARK1 expression and activity in a model of
exaggerated cardiac hypertrophy with increased mortality
(PE-treated Tga43 mice) suggest that bARK1 plays a
unfavorable role in the evolution of cardiac hypertrophy and
its transition to HF.
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